An observational study in Acute Leukemia, Newly Diagnosed Acute Leukemia and Thromboprophylaxis, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto · Observational
This is a observational study designed to identify risk factors for venous thromboembolism in patients with newly diagnosed acute leukemia at the time of first admission to a Hematology Ward.
Each patient will be observed for the duration of hospitalization.
This is a prospective, observational cohort study designed to identify risk factors for venous thromboembolism (VTE) in patients with newly diagnosed acute leukemia (AL) at the time of first admission to a Hematology Ward. The study will be conducted within the GIMEMA network of Italian Hematology Centers.
The observation period for each patient will correspond to the duration of hospitalization, starting from the day of admission to the Hematology Ward, irrespective of whether antithrombotic therapy is prescribed.
Gruppo Italiano Malattie EMatologiche dell'Adulto is the lead sponsor of 135 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will include patients with newly diagnosed acute leukemia at the time of first admission to a Hematology Ward.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of patients with venous thromboembolism event during hospitalization
Cumulative incidence of the first venous thromboembolism event from hospital admission to discharge or death
Time frame: through study completion, an average of 2 years
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gruppo Italiano Malattie EMatologiche dell'Adulto →